Indivior raises FY 2025 guidance after Q2 beat; SUBLOCADE revenue up 9%

Indivior Pharmaceuticals, Inc.

2025-Q2 EPS reported $0.52 revenue$568,000,000

Q2 total net revenue $302M (+1% YoY); net income $18M ($0.14 EPS); non-GAAP diluted EPS $0.51.
SUBLOCADE net revenue $209M (+9% YoY, +19% vs Q1'25); U.S. SUBLOCADE $195M (+9% YoY).
FY 2025 guidance raised: net revenue $1.03B-$1.08B (prior $955M-$1.025B); adjusted EBITDA $275M-$300M (prior $220M-$260M).
Adjusted EBITDA Q2 $88M vs $93M Q2'24; cash and investments $538M at Q2 end.

item 2.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.